Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

psychiatric diseases

- PMLiVE

Boehringer files nintedanib for lung cancer in Europe

Pharma company seeks approval for second oncology drug

- PMLiVE

Lilly enters cancer collaboration in China

Signs deal with Chi-Med to develop and commercialise fruquintinib

- PMLiVE

Boehringer shuts Ben Venue unit

About 1,100 jobs expected to be lost at troubled manufacturing site

- PMLiVE

New US drug discovery institute partners with Takeda

Tri-Institutional Therapeutics Discovery Institute to cover communicable, chronic and rare conditions

- PMLiVE

ECC 2013: Nintedanib data boosts Boehringer’s oncology ambitions

Lung cancer drug shows extended overall survival in adenocarcinoma patients

- PMLiVE

Boehringer’s oncology unit scores first EU approval

Giotrif given green light for non-small cell lung cancer

- PMLiVE

EASD 2013: Pharma backs public/private diabetes research collaboration

Sanofi, Lilly and Boehringer support part of IMI Diabetes Platform

- PMLiVE

Boehringer to work with Roche on cancer diagnostics

Will collaborate with Roche subsidiary Ventana Medical Systems

- PMLiVE

Hikma pushes further into Africa with Ethiopian JV

Forms alliance with MIDROC to create HikmaCure

Covance to collaborate with Indiana University on trials

Will work with the US university on pharma and biotech studies

- PMLiVE

Boehringer creates ‘Captain Zantac’

Animated fireman fronts marketing campaign in US for heartburn remedy

- PMLiVE

Eisai lines-up Fycompa access programme for Germany

But sales suspension for epilepsy drug will continue

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links